Notícias e Atividades da SV Health Investors

SV Health Investors tem presença direta em 2 países.

Veja o organograma con seus 39 executivos principais

Biografias mais buscadas da SV Health Investors

• Eugene Hill, Chairman of the Board
• Brent Faduski, Chief Financial Officer, Chief Compliance Officer a...
• Greg Madden, Managing Partner, Medical Devices and Healthcare

Recentes movimentos de executivos em SV Health Investors

• A.J. Rossi antes Principal, Healthcare Growth-Buyout, foi promovido a Partner, Healthcare Growth-Buyout  (Notícia publicada em 23 de dezembro de 2024).

Criar um alerta
para seguir os movimentos de executivos da SV Health Investors.

SV Health Investors possui 1.564 concorrentes concorrentes BlackRock (Estados Unidos), Vanguard (Estados Unidos) e Blackstone Group (Estados Unidos).

Popular M&A news in Fundo

• Seven2 has announced the acquisition of HRK Lunis  (publicado em 3 de abril de 2025).
• Fluent adquiriu RIV Capital (publicado em 20 de dezembro de 2024).
• RIV Capital and Fluent have announced they will merge  (publicado em 14 de outubro de 2024)..

Outros contatos sugeridos na indústria do Fundo

• Antonio Gracias - Founder, Chief Executive Officer and Chief Investment Officer da Valor Equity Partners
• Salim Ramji - Chief Executive Officer and Director da Vanguard
• Hemant Taneja - Chief Executive Officer and Managing Director da General Catalyst Partners

Saiba mais sobre a indústria do Fundo

Últimos comunicados de imprensa de SV Health Investors

• News - SV Health Investors
• Endlyz Therapeutics launches and unveils its portfolio of programmes targeting Parkinson’s disease - SV Health Investors
• British Patient Capital announces £25m commitment to SV Health Investors’ Dementia Discovery Fund 2 - SV Health Investors
• Sitryx initiates Phase 1 clinical trial of potential disease-modifying treatment for atopic dermatitis SYX-5219 - SV Health Investors
• Nitrase Therapeutics Unveils Protein with Newly Characterized Enzymatic Function Involved in the Pathogenesis of Parkinson’s Disease - SV Health Investors
• Montara Therapeutics Closes $20M Oversubscribed Seed Expansion, Appoints Troy Wilson as Chairman of the Board - SV Health Investors
• FDA Approves Expanded Use of Miach Orthopaedics’ BEAR® Implant - SV Health Investors
• QurAlis Announces Topline Data From its Phase 1 Clinical Trial of QRL-101 Evaluating Biomarkers of ALS and Epilepsy in Healthy Volunteers - SV Health Investors
• Mestag Therapeutics Appoints Dr. Matthew Sleeman as Chief Scientific Officer - SV Health Investors
• TRIMTECH Therapeutics raises $31M seed funding to advance targeted protein degradation pipeline for treatment of neurodegenerative diseases - SV Health Investors
• View more press releases Close

Redes sociais sobre SV Health Investors

• SV Health Investors na Wikipedia, Google News e Yahoo Finance
• SV Health Investors na LinkedIn, Twitter e YouTube